Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.

CPT: pharmacometrics & systems pharmacology - 1 Jan 2024

Jung Yun Seob, Jin Byung Hak, Park Min Soo, Kim Choon Ok, Chae Dongwoo

Abstract excerpt

Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects. Herein, we conducted a proof-of-concept study for using population pharmacokinetic-pharmacodynamic (PK-PD) modeling to recommend a personalized clopidogrel dosing regimen for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Genotype

Share to Phenotype

Share to Polymorphism, Genetic

Share to Proof of Concept Study

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 37775990
DOI: 10.1002/psp4.13053
PMCID: PMC10787215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.PMID 37775990Read ↗

A physiologically-based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activitySemantic proximity Read ↗

Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.Semantic proximity Read ↗

Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Semantic proximity Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular MedicineSemantic proximity Read ↗

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and PharmacometabolomicsSemantic proximity Read ↗

Influence of CYP2C19 and ABCB1 Genetic Polymorphisms on Clopidogrel Pharmacokinetics: A PharmGKB Retrospective AnalysisSemantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.Semantic proximity Read ↗

Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank.Semantic proximity Read ↗

Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.